Polo-like kinase 1 inhibitors in human cancer therapy: development and therapeutic potential

J Zhang, L Zhang, J Wang, L Ouyang… - Journal of medicinal …, 2022 - ACS Publications
Polo-like kinase 1 (PLK1) plays an important role in a variety of cellular functions, including
the regulation of mitosis, DNA replication, autophagy, and the epithelial–mesenchymal …

[HTML][HTML] Present and future perspective on PLK1 inhibition in cancer treatment

M Chiappa, S Petrella, G Damia, M Broggini… - Frontiers in …, 2022 - frontiersin.org
Polo-like kinase 1 (PLK1) is the principle member of the well conserved serine/threonine
kinase family. PLK1 has a key role in the progression of mitosis and recent evidence …

[HTML][HTML] Plk1 overexpression induces chromosomal instability and suppresses tumor development

G de Cárcer, SV Venkateswaran, L Salgueiro… - Nature …, 2018 - nature.com
Abstract Polo-like kinase 1 (Plk1) is overexpressed in a wide spectrum of human tumors,
being frequently considered as an oncogene and an attractive cancer target. However, its …

A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia

A Kirtonia, G Pandya, G Sethi, AK Pandey… - Journal of molecular …, 2020 - Springer
Acute myeloid leukemia (AML) is an extremely heterogeneous disease defined by the clonal
growth of myeloblasts/promyelocytes not only in the bone marrow but also in peripheral …

[HTML][HTML] A mechanism for controlled breakage of under-replicated chromosomes during mitosis

H Duda, M Arter, J Gloggnitzer, F Teloni, P Wild… - Developmental cell, 2016 - cell.com
While DNA replication and mitosis occur in a sequential manner, precisely how cells
maintain their temporal separation and order remains elusive. Here, we unveil a double …

Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution

AC Henriques, D Ribeiro, J Pedrosa, B Sarmento… - Cancer letters, 2019 - Elsevier
Current microtubule-targeting agents (MTAs) remain amongst the most important antimitotic
drugs used against a broad range of malignancies. By perturbing spindle assembly, MTAs …

Pharmacoinformatics approach for the identification of Polo-like kinase-1 inhibitors from natural sources as anti-cancer agents

MF AlAjmi, MT Rehman, A Hussain… - International journal of …, 2018 - Elsevier
Abstract Polo-like kinase-1 (PLK-1) plays a key role in cell cycle progression during mitosis.
Overexpression/dysfunction of PLK-1 is directly associated with cancerous transformation …

Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications

I Shakeel, N Basheer, GM Hasan, M Afzal… - Journal of Drug …, 2021 - Taylor & Francis
Abstract Polo-like kinase 1 (PLK1) is a conserved mitotic serine-threonine protein kinase,
functions as a regulatory protein, and is involved in the progression of the mitotic cycle. It …

[HTML][HTML] Aerosol delivery of star polymer-siRNA nanoparticles as a therapeutic strategy to inhibit lung tumor growth

Z Ma, SW Wong, H Forgham, L Esser, M Lai… - Biomaterials, 2022 - Elsevier
Lung cancer is a major contributor to cancer-related death worldwide. siRNA
nanomedicines are powerful tools for cancer therapeutics. However, there are challenges to …

[HTML][HTML] Evolving therapeutic strategies to exploit chromosome instability in cancer

LL Thompson, LMP Jeusset, CC Lepage, KJ McManus - Cancers, 2017 - mdpi.com
Cancer is a devastating disease that claims over 8 million lives each year. Understanding
the molecular etiology of the disease is critical to identify and develop new therapeutic …